A sequence variation in 3′UTR of CYP21A2 gene correlates with a mild form of congenital adrenal hyperplasia

Journal of Endocrinological Investigation

Volumn 35, Issue 3, 2012, Pages 298-305

  Menabo S ^a   Balsamo, A ^a   Baldazzi, L ^a   Barbaro, M ^b   Nicoletti, A ^a   Conti, V ^a   Pirazzoli, P ^a   Wedell, A ^b   Cicognani, A ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

21 hydroxylase; 3 UTR; CAH; Congenital adrenal hyperplasia; CYP21A2

Indexed keywords

CYTOCHROME P450 CYP21A2; STEROID 21 MONOOXYGENASE; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; ADOLESCENT; ADULT; ALLELE; ARTICLE; BIOINFORMATICS; CHILD; CLINICAL ARTICLE; CONGENITAL ADRENAL HYPERPLASIA; CONTROLLED STUDY; DNA SEQUENCE; FEMALE; GENE EXPRESSION; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HUMAN; IN VITRO STUDY; MALE; MULTIPLEX LIGATION DEPENDENT PROBE AMPLIFICATION; NUCLEOTIDE SEQUENCE; PHENOTYPE; RNA FOLDING; SCHOOL CHILD;

3' UNTRANSLATED REGIONS; ADOLESCENT; ADRENAL HYPERPLASIA, CONGENITAL; ADULT; CHILD; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; HAPLOTYPES; HUMANS; MALE; MODELS, GENETIC; NUCLEIC ACID CONFORMATION; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; RETROSPECTIVE STUDIES; RNA, MESSENGER; SEVERITY OF ILLNESS INDEX; STEROID 21-HYDROXYLASE; YOUNG ADULT;

EID: 84862881573     PISSN: 03914097     EISSN: 17208386     Source Type: Journal    
DOI: 10.3275/7680     Document Type: Article

References (44)

1. Speiser PW, Dupont B, Rubinstein P, Piazza A, Kastelan A, New MI. High frequency of nonclassical steroid 21-hydroxylase deficiency. Am J Hum Genet 1985, 37: 650-67.
2. Wilson RC, Nimkarn S, Dumic M, et al. Ethnic-specific distribution of mutations in 716 patients with congenital adrenal hyperplasia owing to 21-hydroxylase deficiency. Mol Genet Metab 2007, 90: 414-21.
3. Kohn B, Levine LS, Pollack MS, et al. Late-Onset Steroid 21- Hydroxylase Deficiency: A Variant of Classical Congenital Adrenal Hyperplasia. J Clin Endocrinol Metab 1982, 55: 817-27.
4. Speiser PW. Nonclassic adrenal hyperplasia. Rev Endocr Metab Disord 2009, 10: 77-82.
5. Yang Z, Mendoza AR, Welch TR, Zipf WB, Yu CY. Modular variations of the human major histocompatibility complex class III genes for serine/threonine kinase RP, complement component C4, steroid 21-hydroxylase CYP21, and tenascinTNX (the RCCX module). A mechanism for gene deletions and disease associations. J Biol Chem 1999, 274: 12147-56.
6. Higashi Y, Yoshioka H, Yamane M, Gotoh O, Fujii-Kuriyama Y. Complete nucleotide sequence of two steroid 21-hydroxylase genes tandemly arranged in human chromosome: a pseudogene and a genuine gene. Proc Natl Acad Sci U S A 1986, 83: 2841-5.
7. White PC, New MI, Dupont B. Structure of human steroid 21-hydroxylase genes. Proc Natl Acad Sci U S A 1986, 83: 5111-5.
8. Billerbeck AE, Mendonca BB, Pinto EM, Madureira G, Arnhold IJ, Bachega TA. Three novel mutations in CYP21 gene in Brazilian patients with the classical form of 21-hydroxylase deficiency due to a founder effect. J Clin Endocrinol Metab 2002, 87: 4314-7.
9. Lee HH. CYP21 mutations and congenital adrenal hyperplasia. Clin Genet 2001, 59: 293-301.
10. White PC, Speiser PW. Congenital adrenal hyperplasia due to 21- hydroxylase deficiency. Endocr Rev 2000, 21: 245-91.
11. Krone N, Arlt W. Genetics of congenital adrenal hyperplasia. Best Pract Res Clin Endocrinol Metab 2009, 23: 181-92.
12. Deneux C, Tardy V, Dib A, et al. Phenotype-genotype correlation in 56 women with nonclassical congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Clin Endocrinol Metab 2001, 86: 207-13.
13. Bidet M, Bellanné-Chantelot C, Galand-Portier MB, et al. Clinical and molecular characterization of a cohort of 161 unrelated women with nonclassical congenital adrenal hyperplasia due to 21-hydroxylase deficiency and 330 family members. J Clin Endocrinol Metab 2009, 94: 1570-8.
14. Barbat B, Bogyo A, Raux-Demay MC, et al. Screening of CYP21 gene mutations in 129 French patients affected by steroid 21-hydroxylase deficiency. Hum Mutat 1995, 5: 126-30.
15. Carrera P, Bordone L, Azzani T, et al. Point mutations in Italian patients with classic, non-classic, and cryptic forms of steroid 21-hydroxylase deficiency. Hum Genet 1996, 98: 662-5.
16. Bachega TA, Billerbeck AE, Madureira G, et al. Molecular genotyping in Brazilian patients with the classical and nonclassical forms of 21-hydroxylase deficiency. J Clin Endocrinol Metab 1998, 83: 4416-9.
17. Weintrob N, Brautbar C, Pertzelan A, et al. Genotype-phenotype associations in non-classical steroid 21-hydroxylase deficiency. Eur J Endocrinol 2000, 143: 397-403.
18. Friães A, Rêgo AT, Aragüés JM, et al. CYP21A2 mutations in Portuguese patients with congenital adrenal hyperplasia: Identification of two novel mutations and characterization of four different partial gene conversions. Mol Genet Metab 2006, 88: 58-65.
19. Dolzan V, Sólyom J, Fekete G, et al. Mutational spectrum of steroid 21-hydroxylase and the genotype-phenotype association in Middle European patients with congenital adrenal hyperplasia. Eur J Endocrinol 2005, 153: 99-106.
20. Kotaska K, Prusa R. Frequency of CYP21 gene mutations in Czech patients with steroid 21-hydroxylase deficiency and statistical comparison with other populations. Med Princ Pract 2003, 12: 243-7.
21. Stikkelbroeck NM, Hoefsloot LH, de Wijs IJ, Otten BJ, Hermus AR, Sistermans EA. CYP21 gene mutation analysis in 198 patients with 21-hydroxylase deficiency in The Netherlands: six novel mutations and a specific cluster of four mutations. J Clin Endocrinol Metab 2003, 88: 3852-9.
22. Dolzan V, Stopar-Obreza M, Zerjav-Tansek M, Breskvar K, Krzisnik C, Battelino T. Mutational spectrum of congenital adrenal hyperplasia in Slovenian patients: a novel Ala15Thr mutation and Pro30Leu within a larger gene conversion associated with a severe form of the disease. Eur J Endocrinol 2003, 149: 137-44.
23. Barbaro M, Lajic S, Baldazzi L, et al. Functional analysis of two recurrent amino acid substitutions in the CYP21 gene from Italian patients with congenital adrenal hyperplasia. J Clin Endocrinol Metab 2004, 89: 2402-7.
24. Balsamo A, Baldazzi L, Menabò S, Cicognani A. Impact of molecular genetics on congenital adrenal hyperplasia management. Sex Dev 2010, 4: 233-48.
25. Balsamo A, Cacciari E, Baldazzi L, et al. CYP21 analysis and phenotype/ genotype relationship in the screened population of the Italian Emilia-Romagna region. Clin Endocrinol 2000, 53: 117-25.
26. Chen J, Férec C, Cooper DN. A systematic analysis of disease-associated variants in the 3′ regulatory regions of human proteincoding genes II: the importance of mRNA secondary structure in assessing the functionality of 3′ UTR variants. Hum Genet 2006, 120: 301-33.
27. Griffiths-Jones S, Grocock RJ, van Dongen S, Bateman A, Enright AJ. miRBase: microRNA sequences, targets and gene nomenclature. Nucleic Acids Res 2006, 34: D140-4.
28. John B, Enright AJ, Aravin A, Tuschl T, Sander C, Marks DS. Human MicroRNA targets. PLoS Biol 2004, 2: e363.
29. Lewis BP, Shih IH, Jones-Rhoades MW, Bartel DP, Burge CB. Prediction of mammalian microRNA targets. Cell 2003, 115: 787-98.
30. Krek A, Grün D, Poy MN, et al. Combinatorial microRNA target predictions. Nat Genet 2005, 37: 495-500.
31. Kiriakidou M, Nelson PT, Kouranov A, et al. A combined computational- experimental approach predicts human microRNA targets. Genes Dev 2004, 18: 1165-78.
32. Lajic S, Levo A, Nikoshkov A, Lundberg Y, Partanen J, Wedell A. A cluster of missense mutations at Arg356 of human steroid 21-hydroxylase may impair redox partner interaction. Hum Genet 1997, 99: 704-9.
33. Nikoshkov A, Lajic S, Holst M, Wedell A, Luthman H. Synergistic effect of partially inactivating mutations in steroid 21-hydroxylase deficiency. J Clin Endocrinol Metab 1997, 82: 194-9.
34. Giwercman YL, Nordenskjöld A, Ritzén EM, et al. An androgen receptor gene mutation (E653K) in a family with congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency as well as in partial androgen insensitivity. J Clin Endocrinol Metab 2002, 87: 2623-8.
35. Ezquieta B, Beneyto M, Muñoz-Pacheco R, et al. Gene duplications in 21-hydroxylase deficiency: the importance of accurate molecular diagnosis in carrier detection and prenatal diagnosis. Prenat Diagn 2006, 26: 1172-8.
36. Ezquieta B, Cueva E, Varela J, Oliver A, Fernández J, Jariego C. Non-classical 21-hydroxylase deficiency in children: association of adrenocorticotropic hormone-stimulated 17-hydroxyprogesterone with the risk of compound heterozygosity with severe mutations. Acta Paediatr 2002, 91: 892-8.
37. Bachega TA, Billerbeck AE, Marcondes JA, Madureira G, Arnhold IJ, Mendonca BB. Influence of different genotypes on 17-hydroxyprogesterone levels in patients with nonclassical congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Clin Endocrinol 2000, 52: 601-7.
38. Chen J, Férec C, Cooper D. A systematic analysis of disease-associated variants in the 3′ regulatory regions of human protein-coding genes I: general principles and overview. Hum Genet 2006, 120: 1-21.
39. Seffens W, Digby D. mRNAs have greater negative folding free energies than shuffled or codon choice randomized sequences. Nucleic Acids Res 1999, 27: 1578-84.
40. Sgourou A, Papachatzopoulou A, Psiouri L, et al. The beta-globin C → G mutation at 6 bp 3′ to the termination codon causes beta-thalassaemia by decreasing the mRNA level. Br J Haematol 2002, 118: 671-6.
41. Admoni O, Israel S, Lavi I, Gur M, Tenenbaum-Rakover Y. Hyperandrogenism in carriers of CYP21 mutations: the role of genotype. Clin Endocrinol (Oxf) 2006, 64: 645-51.
42. Weintrob N, Brautbar C, Pertzelan A, et al. Genotype-phenotype associations in non-classical steroid 21-hydroxylase deficiency. Eur J Endocrinol 2000, 143: 397-403.
43. Witchel SF, Lee PA. Identification of heterozygotic carriers of 21-hydroxylase deficiency: sensitivity of ACTH stimulation tests. Am J Med Genet 1998, 76: 337-42.
44. New MI. Extensive clinical experience: nonclassical 21-hydroxylase deficiency. J Clin Endocrinol Metab 2006, 91: 4205-14.